GR1803 Injection in Patients With RRMM

All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.

NCT Number	NCT06952075
Lead Sponsor	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions	Multiple Myleoma
Enrollment	30 participants
Start Date	2025-04-24
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-30